Hologic, Inc. (NASDAQ:HOLX) Shares Acquired by Geode Capital Management LLC

Geode Capital Management LLC raised its position in Hologic, Inc. (NASDAQ:HOLX) by 2.6% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 5,732,131 shares of the medical equipment provider’s stock after purchasing an additional 144,838 shares during the period. Geode Capital Management LLC’s holdings in Hologic were worth $412,159,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Norges Bank bought a new position in Hologic during the fourth quarter worth $133,414,000. Boston Partners raised its holdings in shares of Hologic by 81.0% during the fourth quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider’s stock valued at $257,959,000 after buying an additional 1,602,463 shares during the last quarter. Nordea Investment Management AB boosted its position in shares of Hologic by 32.7% during the fourth quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider’s stock worth $159,911,000 after buying an additional 544,889 shares during the period. Raymond James Financial Inc. bought a new position in Hologic in the 4th quarter worth approximately $27,007,000. Finally, Arrowstreet Capital Limited Partnership increased its holdings in shares of Hologic by 27.3% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,687,347 shares of the medical equipment provider’s stock valued at $121,641,000 after purchasing an additional 361,539 shares during the period. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Stock Down 1.3 %

Shares of Hologic stock opened at $60.86 on Friday. Hologic, Inc. has a 1 year low of $59.06 and a 1 year high of $84.67. The company has a market cap of $13.66 billion, a P/E ratio of 19.20, a P/E/G ratio of 2.14 and a beta of 0.97. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The stock has a 50-day moving average price of $64.30 and a 200 day moving average price of $72.65.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, analysts expect that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on HOLX shares. BNP Paribas upgraded shares of Hologic to a “strong-buy” rating in a report on Tuesday, December 10th. Jefferies Financial Group assumed coverage on shares of Hologic in a research report on Tuesday, December 10th. They issued a “hold” rating and a $85.00 price target on the stock. Wolfe Research started coverage on shares of Hologic in a research report on Friday, December 13th. They set a “peer perform” rating for the company. Royal Bank of Canada lowered their price objective on shares of Hologic from $88.00 to $85.00 and set a “sector perform” rating on the stock in a research note on Thursday, February 6th. Finally, Morgan Stanley cut their target price on shares of Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Eleven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Hologic has an average rating of “Hold” and a consensus target price of $84.62.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.